Analysts See $-0.25 EPS for Infinity Pharmaceuticals, Inc. (INFI); Mesa Royalty Trust (MTR) Sentiment Is 2.33

February 13, 2018 - By Marie Mckinney

Analysts expect Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) to report $-0.25 EPS on March, 13.They anticipate $0.21 EPS change or 45.65% from last quarter’s $-0.46 EPS. After having $-0.14 EPS previously, Infinity Pharmaceuticals, Inc.’s analysts see 78.57% EPS growth. The stock decreased 1.65% or $0.03 during the last trading session, reaching $1.79. About 224,293 shares traded. Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) has declined 60.96% since February 13, 2017 and is downtrending. It has underperformed by 77.66% the S&P500.

Mesa Royalty Trust holds net overriding royalty interests in various gas and oil properties in the United States. The company has market cap of $27.67 million. It has interests in properties located in the Hugoton field of Kansas; the San Juan Basin field of New Mexico and Colorado; and the Yellow Creek field of Wyoming. It has a 11.28 P/E ratio.

Greenwich Investment Management Inc. holds 0.29% of its portfolio in Mesa Royalty Trust for 14,449 shares. Hawkins Capital L.P. owns 23,599 shares or 0.15% of their US portfolio. Moreover, Northwest Investment Counselors Llc has 0.01% invested in the company for 799 shares. The Georgia-based Advisory Services Network Llc has invested 0% in the stock. Bank Of America Corp De, a North Carolina-based fund reported 8,216 shares.

The stock decreased 1.66% or $0.25 during the last trading session, reaching $14.85. About 4,106 shares traded. Mesa Royalty Trust (MTR) has risen 70.21% since February 13, 2017 and is uptrending. It has outperformed by 53.51% the S&P500.

Infinity Pharmaceuticals, Inc., a biopharmaceutical company, develops medicines for patients with difficult-to-treat diseases in the United States. The company has market cap of $90.77 million. The Company’s lead product candidate includes IPI-549 an orally administered immuno-oncology product candidate that inhibits the enzyme phosphoinositide-3-kinase-gamma is in Phase 1 clinical study. It currently has negative earnings. The firm has a license agreement with Verastem, Inc. to research, develop, commercialize, and manufacture duvelisib, a selective inhibitor of the PI3K delta and gamma isoforms, including DUO study that is in randomized Phase III clinical study for patients with relapsed/refractory chronic lymphocytic leukemia and products containing duvelisib; Intellikine, Inc. to discover, develop, and commercialize pharmaceutical products targeting the delta and/or gamma isoforms of PI3K; and Takeda Pharmaceutical Company Limited to develop and commercialize duvelisib.

Investors sentiment decreased to 0.47 in Q3 2017. Its down 0.16, from 0.63 in 2017Q2. It dropped, as 15 investors sold Infinity Pharmaceuticals, Inc. shares while 23 reduced holdings. 6 funds opened positions while 12 raised stakes. 27.30 million shares or 18.05% less from 33.31 million shares in 2017Q2 were reported. 10,590 were accumulated by Citadel Advsr Ltd Llc. 100 were accumulated by Tortoise Mgmt Lc. Geode Capital Mgmt invested in 0% or 266,503 shares. Nationwide Fund Advsrs holds 0% of its portfolio in Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) for 49,500 shares. 584,048 are held by Millennium Management. Art Advsrs Limited Liability reported 0.01% stake. Platinum Inv Ltd, a Australia-based fund reported 1.41 million shares. Bogle Inv Mngmt L P De reported 224,793 shares stake. Blackrock owns 0% invested in Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) for 1.01 million shares. Financial Bank Of America De invested in 0% or 10,759 shares. Acadian Asset Mngmt Limited Liability Corporation reported 0% in Infinity Pharmaceuticals, Inc. (NASDAQ:INFI). California Employees Retirement accumulated 88,100 shares or 0% of the stock. D E Shaw And invested in 0% or 421,544 shares. Blair William Il accumulated 12,250 shares. Virtu Financial Limited Liability Company holds 0% or 10,339 shares.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: